Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably
It is resetting
doi: 10.1007/s004410051371 13 CapenCCMartinSL
Current and Emerging Medications: Name Type Status Tirzepatide Dual GLP-1 / GIP Agonist FDA Approved CagriSema Dual GLP-1 / Amylin AgonistIn Phase 3 Trials Retatrutide Triple GIP / GLP-1 / GlucagonIn Phase 3 Trials These multi-pathway drugs aim to improve results but may also come with more side effects
None is universally right
M., Rosenstock, J., Srrig, R., Wadden, T
